Quick Answer
Kymera Therapeutics, Inc. reported Diluted EPS of $3.69 per share (loss) for fiscal year 2025.
Kymera Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.69 | -23.8% |
| 2024 | -$2.98 | -18.3% |
| 2023 | -$2.52 | +12.2% |
| 2022 | -$2.87 | -37.3% |
| 2021 | -$2.09 | +33.7% |
| 2020 | -$3.15 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.94 | -14.6% | +1.1% |
| June 30, 2025 | -$0.95 | -63.8% | -15.9% |
| March 31, 2025 | -$0.82 | -18.8% | +0.0% |
| September 30, 2024 | -$0.82 | +8.9% | -41.4% |
| June 30, 2024 | -$0.58 | +13.4% | +15.9% |
| March 31, 2024 | -$0.69 | +1.4% | +23.3% |
| September 30, 2023 | -$0.90 | -13.9% | -34.3% |
| June 30, 2023 | -$0.67 | +14.1% | +4.3% |
- Kymera Therapeutics, Inc. showed a decrease of -23.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Kymera Therapeutics, Inc.’s diluted eps has declined by 17.1% (from $3.15 per share (loss) to $3.69 per share (loss)).
- The most recent figure is from Kymera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: